RA'ANANA, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has successfully achieved all key strategic objectives in its high-level talks with a government health authority, located outside of the United States, on July 8, 2025, a meeting previously announced by the Company on July 7, 2025, establishing a definitive pa ...

Core Insights - Inspira Technologies is engaged in high-level discussions with a government health authority outside the U.S. to integrate its FDA-cleared ART100 system into national emergency infrastructure and establish a global distribution framework [1][2][5] - The meeting scheduled for July 8, 2025, aims to define key terms and a roadmap for this strategic collaboration, initiated by the government seeking next-generation medical technologies [2][3] - The government involved has extensive commercial ties and diplomatic channels, which will be leveraged to enhance the profitability of a recent $22.5 million purchase order received by Inspira [3][4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [6] - The company is also developing the INSPIRA ART500, a next-generation system for oxygenation while patients remain awake, and advancing the HYLA blood sensor platform for continuous, non-invasive monitoring [6] - Recent internal shifts within the company may align with broader industry trends such as consolidation, cross-sector collaboration, and potential strategic partnerships [6]

Core Insights - Inspira Technologies has secured a binding purchase order worth $22.5 million for its FDA-cleared ART100 system, marking a significant commercial milestone for the company [1][3][4] - The order is expected to be fully paid during 2025, with immediate implementation already underway [2] - This purchase order is seen as a small portion of the total addressable market that Inspira is targeting globally, indicating potential for further growth [3] Company Developments - The CEO of Inspira Technologies highlighted that this order reflects confidence in their technology and confirms market demand, paving the way for future global deployments [4] - The company is in advanced negotiations with additional healthcare companies and governmental institutions, which may lead to further commercial agreements soon [4][5] - Recent milestones for the company include successful clinical integration in Tier-1 hospitals and expansion of manufacturing capabilities [5] Product and Market Position - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [6] - The company is also developing the next-generation INSPIRA ART500 system and a proprietary blood sensor platform, HYLA™, which enhances its position in the life-support and MedTech landscape [6] - With multiple cleared products and a growing intellectual property portfolio, Inspira is strategically aligning with long-term industry trends such as consolidation and cross-sector collaboration [6]

RA'ANANA, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that its FDA-cleared ART100 system adoption has begun to positively impact commercialization interest and efforts, representing a key milestone and significantly contributes to the Company's commercial validation. The ART100 system has been successfully integrated into ...

RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the “ART100 system”), in response to expected demand from a European governmental authority with whic ...

RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the “ART100 system”), in response to expected demand from a European governmental authority with which the Company is currently in advanced- ...

Following successful clinical implementations in the U.S., Inspira accelerates commercialization of its system. The Company is already engaged in discussions with governmental health departments and private organizationsRA'ANANA, Israel, May 29, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic shift to accelerate the commercialization of its U.S. FDA (Food ...

RA'ANANA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneering company in advanced respiratory support and diagnostic systems, today announced an evolution in its executive structure that reflects recent internal assessments and long-term strategic alignment efforts. Mr. Joe Hayon, Co-Founder and President of Inspira, will be stepping down from his operational role as President of Inspira, and will continue to serve as an ac ...

RA'ANANA, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel's largest healthcare provider to undergo a clinical validation by leading physicians who intend to use the innovative life-support and diagnostic device during organ transplant procedures.  As part of this advancement, Inspira will deploy the ...

Core Insights - The company has achieved a significant milestone by generating initial revenues from its FDA-cleared life support technology, specifically the INSPIRA™ ART100 systems, deployed in a leading U.S. healthcare facility [1][2][3] - The revenue generated is in the low hundreds of thousands of dollars, marking a successful step in the company's strategy to expand its presence in the U.S. healthcare market [2][3] - The CEO emphasized that this achievement validates the company's innovative technology and its ability to collaborate with top-tier medical institutions, which is crucial for advancing the adoption of its life-support systems [3] Company Overview - Inspira Technologies is focused on developing innovative respiratory support and diagnostic technologies, with its flagship product, the INSPIRA ART500 system, designed to allow patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation [4] - The INSPIRA ART100 system is FDA-cleared for cardiopulmonary bypass procedures and has also received regulatory approvals in Israel for similar applications [4] - The company is also developing the HYLA blood sensor technology for continuous, real-time blood monitoring without the need for blood draws, along with other pipeline products [4] Market Context - The INSPIRA ART500 aims to revolutionize the $19 billion mechanical ventilation market by providing a safer alternative that allows patients to avoid mechanical ventilation during treatment [3] - The company plans to install additional INSPIRA ART100 systems at a second leading academic medical center, further expanding its clinical footprint [2][3]